KR102632670B1 - 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염 - Google Patents

이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염 Download PDF

Info

Publication number
KR102632670B1
KR102632670B1 KR1020227021015A KR20227021015A KR102632670B1 KR 102632670 B1 KR102632670 B1 KR 102632670B1 KR 1020227021015 A KR1020227021015 A KR 1020227021015A KR 20227021015 A KR20227021015 A KR 20227021015A KR 102632670 B1 KR102632670 B1 KR 102632670B1
Authority
KR
South Korea
Prior art keywords
leucine
acetyl
subject
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227021015A
Other languages
English (en)
Korean (ko)
Other versions
KR20220093386A (ko
Inventor
말로리 팩터
마이클 스트럽
Original Assignee
인트라바이오 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인트라바이오 리미티드 filed Critical 인트라바이오 리미티드
Priority to KR1020247003393A priority Critical patent/KR102791288B1/ko
Publication of KR20220093386A publication Critical patent/KR20220093386A/ko
Application granted granted Critical
Publication of KR102632670B1 publication Critical patent/KR102632670B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020227021015A 2016-04-19 2017-04-19 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염 Active KR102632670B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247003393A KR102791288B1 (ko) 2016-04-19 2017-04-19 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB201606834 2016-04-19
GB1606834.8 2016-04-19
KR1020227008412A KR102413754B1 (ko) 2016-04-19 2017-04-19 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
PCT/GB2017/051090 WO2017182802A1 (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227008412A Division KR102413754B1 (ko) 2016-04-19 2017-04-19 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247003393A Division KR102791288B1 (ko) 2016-04-19 2017-04-19 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염

Publications (2)

Publication Number Publication Date
KR20220093386A KR20220093386A (ko) 2022-07-05
KR102632670B1 true KR102632670B1 (ko) 2024-02-01

Family

ID=58633040

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020227008412A Active KR102413754B1 (ko) 2016-04-19 2017-04-19 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
KR1020187032983A Ceased KR20180134398A (ko) 2016-04-19 2017-04-19 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
KR1020227021015A Active KR102632670B1 (ko) 2016-04-19 2017-04-19 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
KR1020247003393A Active KR102791288B1 (ko) 2016-04-19 2017-04-19 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020227008412A Active KR102413754B1 (ko) 2016-04-19 2017-04-19 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
KR1020187032983A Ceased KR20180134398A (ko) 2016-04-19 2017-04-19 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247003393A Active KR102791288B1 (ko) 2016-04-19 2017-04-19 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염

Country Status (27)

Country Link
US (4) US10905670B2 (enExample)
EP (2) EP3445351B1 (enExample)
JP (3) JP7387264B2 (enExample)
KR (4) KR102413754B1 (enExample)
CN (2) CN109069463B (enExample)
AU (2) AU2017252507B2 (enExample)
BR (1) BR112018071547A2 (enExample)
CA (1) CA3021155A1 (enExample)
DK (1) DK3445351T3 (enExample)
ES (1) ES2994242T3 (enExample)
FI (1) FI3445351T3 (enExample)
HR (1) HRP20241552T1 (enExample)
HU (1) HUE069219T2 (enExample)
IL (3) IL310508A (enExample)
LT (1) LT3445351T (enExample)
MD (1) MD3445351T2 (enExample)
MX (2) MX388461B (enExample)
NZ (1) NZ747307A (enExample)
PL (1) PL3445351T3 (enExample)
PT (1) PT3445351T (enExample)
RS (1) RS66142B1 (enExample)
RU (1) RU2745912C2 (enExample)
SG (2) SG11201809031XA (enExample)
SI (1) SI3445351T1 (enExample)
SM (1) SMT202400459T1 (enExample)
WO (1) WO2017182802A1 (enExample)
ZA (1) ZA201806849B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102413754B1 (ko) * 2016-04-19 2022-06-27 인트라바이오 리미티드 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
PL3416631T3 (pl) 2016-08-11 2019-11-29 Intrabio Ltd Środki terapeutyczne do leczenia chorób neurodegeneracyjnych
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
WO2020115715A1 (en) 2018-12-06 2020-06-11 Intrabio Ltd. Deuterated analogs of acetyl-leucine
IL321899A (en) * 2019-03-02 2025-09-01 Intrabio Ltd Leucine, acetyl leucine and related analogs for the treatment of disease
US20250099355A1 (en) * 2023-07-18 2025-03-27 Sytheon Ltd Amino acid based salts, compositions and methods for treating skin and improving skin rejuvenation and longevity
US12403111B2 (en) 2024-02-02 2025-09-02 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
EP2152280A1 (en) * 2007-05-08 2010-02-17 Northern Innovations And Formulations Corp. Branched-chain amino acid composition for improving skeletal muscle protein metabolism
WO2011025518A1 (en) * 2009-08-27 2011-03-03 Albert Einstein College Of Medicine Of Yeshiva University Cognitive function training to improve motor ability
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
KR102413754B1 (ko) 2016-04-19 2022-06-27 인트라바이오 리미티드 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
US12458614B2 (en) * 2017-10-18 2025-11-04 Intrabio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Aging and Disease, 6(1), 38-47, 2015.*
European Journal of Pharmacology, 769, 342-349, 2015.*
Journal of Neurology, 260(10), 2556-2561, 2013.*

Also Published As

Publication number Publication date
MD3445351T2 (ro) 2024-12-31
RU2018140131A3 (enExample) 2020-05-14
MX2021014844A (es) 2022-01-18
CN118593463A (zh) 2024-09-06
LT3445351T (lt) 2024-11-25
KR20240018683A (ko) 2024-02-13
MX2018012739A (es) 2019-06-17
EP3445351B1 (en) 2024-10-16
RU2021107001A (ru) 2021-04-12
KR20220038814A (ko) 2022-03-29
SG11201809031XA (en) 2018-11-29
KR20180134398A (ko) 2018-12-18
SMT202400459T1 (it) 2025-01-14
NZ747307A (en) 2025-10-31
RU2018140131A (ru) 2020-05-14
JP2024123087A (ja) 2024-09-10
JP2019513814A (ja) 2019-05-30
EP4501406A2 (en) 2025-02-05
RU2745912C2 (ru) 2021-04-02
KR102413754B1 (ko) 2022-06-27
US11998518B2 (en) 2024-06-04
IL293266B2 (en) 2024-07-01
IL262379B (en) 2022-07-01
WO2017182802A1 (en) 2017-10-26
FI3445351T3 (fi) 2024-11-18
IL293266A (en) 2022-07-01
KR102791288B1 (ko) 2025-04-03
HRP20241552T1 (hr) 2025-01-17
MX388461B (es) 2025-03-20
US20210106548A1 (en) 2021-04-15
IL293266B1 (en) 2024-03-01
BR112018071547A2 (pt) 2019-03-06
AU2017252507A1 (en) 2018-11-08
US20230346732A1 (en) 2023-11-02
KR20220093386A (ko) 2022-07-05
CA3021155A1 (en) 2017-10-26
US20190083438A1 (en) 2019-03-21
US20250332133A1 (en) 2025-10-30
HUE069219T2 (hu) 2025-02-28
EP3445351A1 (en) 2019-02-27
IL310508A (en) 2024-03-01
JP7506046B2 (ja) 2024-06-25
AU2017252507B2 (en) 2022-07-21
DK3445351T3 (da) 2024-11-04
CN109069463B (zh) 2024-07-23
SI3445351T1 (sl) 2025-04-30
EP4501406A3 (en) 2025-03-26
RS66142B1 (sr) 2024-12-31
SG10202106190RA (en) 2021-07-29
JP7387264B2 (ja) 2023-11-28
ES2994242T3 (en) 2025-02-05
AU2022256077A1 (en) 2022-11-17
US12329733B2 (en) 2025-06-17
IL262379A (en) 2018-11-29
PT3445351T (pt) 2024-11-14
US10905670B2 (en) 2021-02-02
JP2022024058A (ja) 2022-02-08
PL3445351T3 (pl) 2025-01-07
CN109069463A (zh) 2018-12-21
ZA201806849B (en) 2019-07-31

Similar Documents

Publication Publication Date Title
KR102632670B1 (ko) 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
AU2023202121B2 (en) Therapeutic agents for neurodegenerative diseases
US12458614B2 (en) Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
RU2837641C2 (ru) Ацетиллейцин или его фармацевтически приемлемая соль для улучшения двигательной функции и когнитивной функции
HK40114671A (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
HK1262576B (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility
HK1262576A1 (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility
NZ787419A (en) Acetyl-Leucine or a Pharmaceutically Acceptable Salt Thereof for Improved Mobility and Cognitive
BR122024012307A2 (pt) Uso de acetil-leucina ou um sal farmaceuticamente aceitável desta

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601